Sanjivani Parenteral Limited , a WHO-GMP certified pharmaceutical company specializing in injectables and oral solids, has reported a steady performance in the first quarter. The company's revenue grew by 8.9% year-over-year to INR 17.90 crores, driven by new product introductions and volume expansion in existing markets.

Financial Highlights

Operational Performance

The company maintained an export-domestic revenue mix of 73.70%-26.30%, with exports to over 25 countries. The product mix comprised 50.20% injectables, 49.30% tablets, and 0.40% nutraceuticals.

Pune Facility Update

Sanjivani Parenteral's new facility in Pune has completed validation batches and final audits. The company expects to receive the commercial license this month, with commercial production slated to begin by the end of August or early September.

Growth Initiatives

• Added 8 new products in Q1 and Q2 combined
• Focusing on expanding presence in LATAM markets and French-speaking African countries
• Expects to ramp up the Pune facility to 65-70% capacity in the first year of operations

Management Commentary

Mr. Srivardhan Khemka, Executive Director, stated, "Despite facing logistical challenges and supply chain bottlenecks, we have maintained our growth trajectory. The underlying demand remains intact, and we are confident of delivering stronger performance in the coming quarters."

Future Outlook

• Revenue guidance of INR 75-80 crores for the full fiscal year
• EBITDA margins expected to remain around 15%
• Anticipates improved performance in upcoming quarters

Challenges and Opportunities

The company faced some headwinds due to global supply chain disruptions, including container availability issues and shipping route diversions. However, management remains optimistic about growth prospects, particularly in Latin American markets where Sanjivani ranks among the top 10 players in the injectable space.

Sanjivani Parenteral continues to focus on expanding its product portfolio and geographical reach, positioning itself for sustained growth in the pharmaceutical sector.

Disclaimer: This article is based on the Q1 earnings call transcript of Sanjivani Parenteral Limited and does not constitute investment advice.

Sanjivani Paranteral Limited , a Mumbai-based pharmaceutical company specializing in parenteral and oral solid products, has reported a steady performance for the quarter ended June 30, 2025 (Q1 FY26), despite challenges in the global trade environment.

Financial Highlights

• Revenue from operations grew by 8.9% year-over-year to ₹178.90 crore
• EBITDA increased by 10.8% to ₹26.80 crore, with margin expanding to 15.0%
• Profit After Tax (PAT) grew marginally by 1.0% to ₹17.30 crore

Segment Performance

The company's performance was marked by contrasting results across its business segments:

• Injectables: Showed robust growth, with revenue increasing by 47.1% year-over-year to ₹89.90 crore
• Oral Segment: Experienced a decline of 11.1% to ₹88.20 crore, attributed to shipment challenges arising from macro uncertainties

Market-Wise Performance

Sanjivani Paranteral's export business continued to be a significant contributor to its overall revenue:

• Exports (including export incentives) constituted 73.7% of total revenue
• Domestic sales accounted for the remaining 26.3%
• Core markets of CIS (including Russia), the Middle East & Africa, and Latin America accounted for 73.7% of revenue, amounting to ₹131.90 crore

Management Commentary

Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral Ltd., commented on the results: "We are pleased to report a steady performance for Q1FY26, in the backdrop of challenges and uncertainties in the global trade environment. While the injectables segment reported strong growth, the oral segment was impacted by shipment-related challenges due to macro uncertainties. This will improve as we look into the coming quarters."

Mr. Khemka also emphasized the company's commitment to its long-term strategy, stating, "We are actively investing in R&D to expand our product portfolio. The continued performance of our export markets, which contributed significantly to our overall revenue, is a testament to this strategy."

Future Outlook

Despite the challenges posed by a dynamic global environment, Sanjivani Paranteral's management expressed confidence in achieving significant revenue growth going forward. The company's diversified portfolio and strategic focus are expected to play crucial roles in this growth trajectory.

Financial Summary Table

Sanjivani Paranteral Limited continues to navigate the complex global pharmaceutical landscape, leveraging its strong presence in export markets and focusing on research and development to drive future growth.